STOCK TITAN

HeartSciences Warrant (HSCSW) DEF 14A Filings

HSCSW NASDAQ

Here are the DEF 14A proxy statements from HeartSciences Inc. Warrant (HSCSW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.

Rhea-AI Summary

HeartSciences Inc. is calling a virtual annual shareholder meeting on April 30, 2026 to vote on several governance and compensation matters. Shareholders of common stock and Series C preferred stock as of March 6, 2026 may participate and vote.

Key items include re-electing Andrew Simpson as the Class III director, and expanding the 2023 Equity Incentive Plan to reserve up to 1,250,000 shares of common stock plus an automatic “evergreen” increase. Shareholders will also vote on adding officer exculpation language to the certificate of formation, within limits allowed by recent Texas law.

Other proposals ask shareholders to ratify Haskell & White LLP as auditor for the year ending April 30, 2026 and to authorize potential adjournment of the meeting if additional proxy solicitation is needed. The proxy describes board structure, committee independence, director pay and current ownership, with three of five directors classified as independent.